These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9671335)

  • 1. Focus on epoetin: key findings of mini-sessions.
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):69-75. PubMed ID: 9671335
    [No Abstract]   [Full Text] [Related]  

  • 2. Improvement in quality of life for cancer patients treated with epoetin alfa.
    Libretto SE; Barrett-Lee PJ; Branson K; Gorst DW; Kaczmarski R; McAdam K; Stevenson P; Thomas R
    Eur J Cancer Care (Engl); 2001 Sep; 10(3):183-91. PubMed ID: 11829381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of cancer-related anemia: epoetin alfa and quality of life.
    Soignet S
    Semin Hematol; 2000 Oct; 37(4 Suppl 6):9-13. PubMed ID: 11068950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer.
    Adamson JW; Ludwig H
    Oncology; 1999; 56(1):46-53. PubMed ID: 9885377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.
    Quirt I; Robeson C; Lau CY; Kovacs M; Burdette-Radoux S; Dolan S; Tang SC; McKenzie M; Couture F;
    J Clin Oncol; 2001 Nov; 19(21):4126-34. PubMed ID: 11689580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoetin alfa improves quality of life in patients with cancer: results of metaanalysis.
    Jones M; Schenkel B; Just J; Fallowfield L
    Cancer; 2004 Oct; 101(8):1720-32. PubMed ID: 15386341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Italian gynecological consensus statement on the use of epoetin alfa in the management of anemia.
    Pecorelli S;
    Semin Oncol; 2002 Jun; 29(3 Suppl 8):13-5. PubMed ID: 12082648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epoetin alfa: recent strategies of use].
    Tumori; 1997; 83(6):975-8. PubMed ID: 9537918
    [No Abstract]   [Full Text] [Related]  

  • 9. Epoetin alfa for treatment of anemia in HIV-infected patients: past, present, and future.
    Henry DH; Volberding PA; Leitz G
    J Acquir Immune Defic Syndr; 2004 Oct; 37(2):1221-7. PubMed ID: 15385728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
    Tonelli M; Owen WF; Jindal K; Winkelmayer WC; Manns B
    Kidney Int; 2004 Oct; 66(4):1712; author reply 1712-3. PubMed ID: 15458473
    [No Abstract]   [Full Text] [Related]  

  • 11. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population.
    Cella D; Zagari MJ; Vandoros C; Gagnon DD; Hurtz HJ; Nortier JW
    J Clin Oncol; 2003 Jan; 21(2):366-73. PubMed ID: 12525531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Epoetin alfa on hemostasis in chronic renal failure.
    Tang WW; Stead RA; Goodkin DA
    Am J Nephrol; 1998; 18(4):263-73. PubMed ID: 9653828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy.
    Itri LM
    Nephrol Dial Transplant; 2001 Dec; 16(12):2289-93. PubMed ID: 11733616
    [No Abstract]   [Full Text] [Related]  

  • 14. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
    Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of epoetin in chronic renal failure.
    Coyne DW
    JAMA; 2007 Apr; 297(15):1713-6. PubMed ID: 17440149
    [No Abstract]   [Full Text] [Related]  

  • 16. Racial differences in erythropoietin responsiveness.
    Kaufman JS
    Am J Kidney Dis; 2008 Dec; 52(6):1035-8. PubMed ID: 19026356
    [No Abstract]   [Full Text] [Related]  

  • 17. Epoetin dosing and dialysis facility ownership.
    Kliger AS; Nissenson AR
    JAMA; 2007 Aug; 298(8):861-2; author reply 862-3. PubMed ID: 17712067
    [No Abstract]   [Full Text] [Related]  

  • 18. Should all patients with chronic kidney disease receive an EPO-type drug?
    Berns JS
    Cleve Clin J Med; 2006 Mar; 73(3):298-300. PubMed ID: 16548453
    [No Abstract]   [Full Text] [Related]  

  • 19. Epoetin dosing and dialysis facility ownership.
    Regidor DL; Kalantar-Zadeh K; Kovesdy CP
    JAMA; 2007 Aug; 298(8):862; author reply 862-3. PubMed ID: 17712068
    [No Abstract]   [Full Text] [Related]  

  • 20. Case history. 1: the use of epoetin alfa in delayed anaemia.
    Mertelsmann R
    Ann Oncol; 1997; 8 Suppl 3():S11-2. PubMed ID: 9341960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.